Fulvestrant
Overview
Fulvestrant is an estrogen receptor antagonist used in the treatment of hormone receptor-positive metastatic breast cancer. It binds to estrogen receptors and promotes their degradation, thereby inhibiting their biological activity.
API suppliers (14)
Suppliers of Fulvestrant evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 13 of 14 suppliers.
7 of 14 hold a GMP certificate on record in the EU or UK registers
- CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO LTDChina1 active DMF
- SCINOPHARM TAIWAN LTDTaiwan1 active DMF
- FARMABIOS SPAItaly1 active DMF
- TAPI NL BVNetherlands1 active DMF
- STERLING SPAItaly1 active DMF GMP on record
- Jiangsu Hansoh Pharmaceutical Group Company LimitedChina1 active DMF GMP on record
- STEROID SPAItaly1 active DMF GMP on record
- INDUSTRIALE CHIMICA SRLItaly1 active DMF GMP on record
- WAVELENGTH ENTERPRISES LTDIsrael1 active DMF GMP on record
- GLAND PHARMA LTDIndia1 active DMF GMP on record
- HANGZHOU JIUYUAN GENE ENGINEERING CO LTDChina1 active DMF
- SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTDChina1 active DMF
- CHEM WERTH INC
- Teva Pharmaceutical Industries Ltd.Israel GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (15 approved US products), the latest listed US patent on Fulvestrant expires 17 May 2034. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Fulvestrant? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.